WHO ICTRP trial
A phase I/ II, non-randomized, feasibility/ safety and efficacy study of the…
EUCTR2008-007686-24-NL · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2008-007686-24-NL |
|---|---|
| Public title | A phase I/ II, non-randomized, feasibility/ safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with metastatic pancreatic cancer - CEC |
| Scientific title | A phase I/ II, non-randomized, feasibility/ safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with metastatic pancreatic cancer - CEC |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Netherlands |
| Conditions | patients with metatastatic pancreatic cancer |
| Interventions | Product Name: certican Product Code: SE/H/356/03 Pharmaceutical Form: Tablet Product Name: capecitabine Product Code: EMEA/H/C/316 Pharmaceutical Form: Tablet Product Name: cetuximab Product Code: EMEA/H/C/558 Pharmaceutical Form… |
| Registration date | Nov 25, 2008 |
| Target size | 35 |
| Secondary IDs | 001 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: